Dermatology

Select Publications

Click here for access to readable versions of publications

H.M. Knochelmann, J.D. Horton, S. Liu, K. Armeson, J.M. Kaczmar, M. Wyatt, M. Richardson, S.H. Lomeli, Y. Xiong, E.M. Graboyes, E.J. Lentsch, J.D. Hornig, J. Skoner, S. Stalcup, M.V. Spampinato, E. Garrett-Mayer, E.C. O’Quinn, C. Timmers, M.J. Romeo, C. Krieg, J. Wrangle, M.I. Young, M.P. Rubinstein, T.A. Day, R.S. Lo, C.M. Paulos, D.M. Neskey (2021) Neoadjuvant Presurgical PD-1 Inhibition in Oral Cavity Squamous Cell Carcinoma, Cell Reports Medicine, 2, 100426-1–100426-10.

S. Liu, H.M. Knochelmann, S.H. Lomeli, A. Hong, M. Richardson, Z. Yang, R.J. Lim, C. Dumitras, C. Timmers, M.J. Romeo, C. Krieg, E.C. O’Quinn, J.D. Horton, S.M. Dubinett C.M. Paulos, D.M. Neskey, R.S. Lo (2021) Response and Recurrence Correlates in Patients Treated with Neoadjuvant Anti-PD-1 Therapy for Resectable Oral-Cavity Squamous Cell Carcinoma, Cell Reports Medicine, 2, 100411-1–100411-12.

Y. Wang, S. Liu, Z, Yang, A.P. Algazi, S.H. Lomeli, Y. Wang, M. Othus, A. Hong, X. Wang, C.E. Randolph, A.M. Jones, M.W. Bosenberg, S.D. Byrum, A.J. Tackett, H. Lopez, C.C. Yates, D.B. Solit, A. Ribas, M. Piva, G. Moriceau, R.S. Lo (2021) Anti-PD-1/L1 Lead-In before MAPK Inhibitor Combination Maximizes Antitumor Efficacy and Immunity, Cancer Cell, Aug 18:S1535-6108(21)00402-5. doi: 10.1016/j.ccell.2021.07.023. Online ahead of print.

A. Hong, M. Piva, S. Liu, W. Hugo, S.H. Lomeli, V. Zoete, C.E. Randolph, Z. Yang, Y. Wang, J.J. Lee, S.J. Lo, L. Sun, A. Vega-Crespo, A.J. Garcia, D.B. Shackelford, S.M. Dubinett, P.O. Scumpia, S.D. Byrum, A.J. Tackett, T.R. Donahue, O. Michielin, S.L. Holmen, A. Ribas, G. Moriceau, R.S. Lo (2020) Durable suppression of acquired MEK inhibitor resistance in cancer by sequestering MEK from ERK and promoting anti-tumor T-cell immunity. Cancer Discovery, Dec 14:CD-20-0873. doi: 10.1158/2159-8290.CD-20-0873. Online ahead of print.

J. Ablain, S. Liu, G. Moriceau, R.S. Lo, L.I. Zon (2020) SPRED1 deletion confers resistance to MAPK inhibition in melanoma. Journal of Experimental Medicine, Mar 1;218(3):e20201097. doi: 10.1084/jem.20201097.

A. Ribas, R.S. Lo (2020) Trying for a BRAF slam dunk. Cancer Discovery, May;10(5):640-642. doi: 10.1158/2159-8290.CD-20-0231.

A.P. Algazi, M. Othus, A.I. Daud, R.S. Lo, J.M. Mehnert, T-G Truong, R. Conry, K. Kendra, G.C. Doolittle, J.I. Clark, M.J. Messino, D.F. Moore, C. Lao, B.A. Faller, R. Govindarajan, A. Harker-Murray, L. Dreisbach, J. Moon, K.F. Grossmann, A. Ribas (2020) Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nature Medicine, Oct;26(10):1564-1568. doi: 10.1038/s41591-020-1060-8. Epub 2020 Oct 5.

E. Perez-Guijarro, H.H. Yang, R.E. Araya. R. El Meskini, H.T. Michael, S.K. Vodnala, K.L. Marie, C. Smith, S. Chin, K.C. Lam, A. Thorkelsson, A.J. Iacovelli, A. Kulaga, A. Fon, A.M. Michalowski, W. Hugo, R.S. Lo, N.P. Restifo, S.K. Sharan, T. Van Dyke, R.S. Goldszmid, Z. Weaver Ohler, M.P. Lee, C.P. Day, G. Merlino (2020) Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy, Nature Medicine, May;26(5):781-791. doi: 10.1038/s41591-020-0818-3. Epub 2020 Apr 13.

S.A. Misek, K.A. Appleton, T. Dexheimer, E.M. Lisabeth, R.S. Lo, S.D. Larsen, K.A. Gallo, R.R. Neubig (2020) Rho-mediated MRTF and YAP1 activation contributes to BRAF inhibitor resistance in Sox9High/Sox10Low melanoma cells, Oncogene, Feb;39(7):1466-1483. doi: 10.1038/s41388-019-1074-1. Epub 2019 Oct 28.

D. Huang, K.A. Leslie, D. Guest, O. Yeshcheulova, I.J. Roy, M. Piva, G. Moriceau, T.A. Zangle, R.S. Lo, M.A. Teitell, J. Reed (2018) High-Speed Live-Cell Interferometry: A New Method for Quantifying Tumor Drug Resistance and Heterogeneity. Analytical Chemistry, Mar 6;90(5):3299-3306. doi: 10.1021/acs.analchem.7b04828. Epub 2018 Feb 13.

L. Huang, S. Malu, J.A. McKenzie, M.C. Andrews, A.H. Talukder, T. Tieu, L.J. Williams, Z. Wang, R.M. Mbofung, Z. Wang, R.E. Davis, R.S. Lo, J.A. Wargo, M. Davies, T. Heffernan, W. Peng, R.N. Amaria, J. Roszik, G. Lizee, S.E. Woodman, P. Hwu (2018) The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating MHC class I expression. Clinical Cancer Research, Jul 15;24(14):3366-3376. doi: 10.1158/1078-0432.CCR-17-2483. Epub 2018 Mar 1.

Hong A, Moriceau G, Lu Sun, Lomeli S, Piva M, Damoiseaux R, Holmen SL, Sharpless NE, Hugo W, and R. S. Lo. Exploiting drug addiction mechanisms to select against MAPKi-resistant melanoma. Cancer Discovery. 2017 Sep 18. DOI: 10.1158/2159-8290.CD-17-0682

Song C, Piva M, Sun L1, Hong A, Moriceau G, Kong X, Zhang H, Lomeli S, Qian J, Yu CC, Damoiseaux R, Kelley MC, Dahlman KB, Scumpia PO, Sosman JA, Johnson DB, Ribas A, Hugo W, Lo RS. Recurrent tumor cell-intrinsic and -extrinsic alterations during MAPKi-induced melanoma regression and early adaptation. Cancer Discovery. 2017 Sep 1. pii: CD-17-0401. doi: 10.1158/2159-8290.CD-17-0401

Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, Palaskas N, Abril Rodriguez G, Parisi G, Azhdam A, Chmielowski B, Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA, Tumeh PC, Graeber TG, Lo RS, Comin-Anduix B, Ribas A. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discovery. 2016 Nov 30. pii: CD-16-1223. [Epub ahead of print]. PMID: 27903500

Pan M, Reid MA, Lowman XH, Kulkarni RP, Tran TQ, Liu X, Yang Y, Hernandez-Davies JE, Rosales KK, Li H, Hugo W, Song C, Xu X, Schones DE, Ann DK, Gradinaru V, Lo RS, Locasale JW, Kong M. Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation. Nature Cell Biology. 2016 Oct;18(10):1090-101. doi: 10.1038/ncb3410. PMID: 27617932

Titz B, Lomova A, Le A, Hugo W, Kong X, Ten Hoeve J, Friedman M, Shi H, Moriceau G, Song C, Hong A, Atefi M, Li R, Komisopoulou E, Ribas A, Lo RS, Graeber TG. JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma. Cell discovery. 2016 Sep 6. doi: 10.1038/celldisc.2016.28.  PMID: 27648299

Escuin-Ordinas H, Li S, Xie MW, Sun L, Hugo W, Huang RR, Jiao J, de-Faria FM, Realegeno S, Krystofinski P, Azhdam A, Komenan SM, Atefi M, Comin-Anduix B, Pellegrini M, Cochran AJ, Modlin RL, Herschman HR, Lo RS, McBride WH, Segura T, Ribas A. Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors. Nature Communications. 2016 Aug 1;7:12348. doi: 10.1038/ncomms12348. PMID: 27476449

Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. New England Journal of Medicine. 2016 Jul 13. PMID: 27433843

Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 2016 Apr 17. doi: 10.1111/pcmr.12475. PMID: 27087480

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH 3rd, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH 3rd, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016 Apr 14;532(7598):250-4. doi: 10.1038/nature17392. PMID: 27042933

Hugo W, Zaretsky J, Sun L, Song C, Homet Moreno B, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2016 Mar 24; doi:10.1016/j.cell.2016.02.065.

Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB, Sosman JA, Ribas A, Lo RS. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell. 2015 Sep 10;162(6):1271-85. doi: 10.1016/j.cell.2015.07.061. PMID: 26359985.

Sanborn JZ, Chung J, Purdom E, Wang NJ, Kakavand H, Wilmott JS, Butler T, Thompson JF, Mann GJ, Haydu LE, Saw RP, Busam KJ, Lo RS, Collisson EA, Hur JS, Spellman PT, Cleaver JE, Gray JW, Huh N, Murali R, Scolyer RA, Bastian BC, Cho RJ. Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):10995-1000. doi: 10.1073/pnas.1508074112. Epub 2015 Aug 18. PMID: 26286987.

Hernandez-Davies JE, Tran TQ, Reid MA, Rosales KR, Lowman XH, Pan M, Moriceau G, Yang Y, Wu J, Lo RS, Kong M. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. J Transl Med. 2015 Jul 3;13:210. doi: 10.1186/s12967-015-0581-2. PMID: 26139106.

Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A. Mol Cancer. 2015 Jul 2;14:128. doi: 10.1186/s12943-015-0393-2. PMID: 26134498.

Obenauf AC, Zou Y, Ji AL, Vanharanta S, Shu W, Shi H, Kong X, Bosenberg MC, Wiesner T, Rosen N, Lo RS, Massagué J. 2015 Mar 25.Therapy-induced tumour secretomes promote resistance and tumour progression. Nature. doi: 10.1038/nature14336. PMID: 25807485.

G. Moriceau, H. Shi, A. Hong, W. Hugo, X. Kong, C.C. Yu, R. C. Koya, A. A. Samatar, N. Khanlou, J. Braun, K. Ruchalski, H. Seifert, J. Larkin, K. B. Dalhman, D. B. Johnson, A. Algazi, J.A. Sosman, A. Ribas, R. S. Lo (2014) Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK co-targeting but result in melanoma drug addiction, Cancer Cell. 2015 Feb 9;27(2):240-56. doi: 10.1016/j.ccell.2014.11.018. PMID:25600339.

J. Muller, O. Krijgsman, J. Tsoi, L. Robert, W. Hugo, C. Song, X. Kong, P.A. Possik, P.D.M. Cornelissen-Steijger, M.H. Geukes Foppen, K. Kemper, C.R. Coding, C. Alifrangis, U. McDermott, C. Blank, J. Haanen, T.G. Graeber, A. Ribas, R.S. Lo and D.S. Peeper (2014) Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma, Nature Communications. 2014 Dec 15;5:5712. doi: 10.1038/ncomms6712. PMID: 25502142.

A.A. Marusiak, Z.C. Edwards, H. Willy, E.W. Trotter, N.L. Stephenson, X. Kong, M.G. Gartside, S. Fawdar, A. Hudson, W. Breitwieser, N.K. Hayward, R.S. Lo, and J. Brognard (2014) Mixed lineage kinases activate the MEK/ERK pathway independently of the RAF kinases: implications for melanoma and resistance to RAF inhibitors, Nature Communications May 22;5:3901. doi: 10.1038/ncomms4901. PMID: 24849047

D.J.L. Wong, L. Robert, M. Atefi, A. Lassen, M. Cerniglia, E. Avramis, J. Tsoi, D. Foulad, T.G. Graeber, B. Comin-Anduix, A. Samatar, R.S. Lo and A. Ribas (2014) Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild type melanoma, Mol Cancer. Aug 20;13(1):194. doi:10.1186/1476-4598-13-194. PMID: 25142146.

T.J. Parmenter, M. Kleinschmidt, K.M. Kinross, S.T. Bond, J. Li, M.R. Kaadige, K.E. Sheppard, W. Hugo, G.M. Pupo, R.B. Pearson, S.L. McGee, G.V. Long, R.A. Scolyer, H. Rizos, R.S. Lo, C. Cullinane, D.E. Ayer, A. Ribas, R.W. Johnstone, R.J. Hicks, G.A. McArthur (2014) Response of BRAF mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis, Cancer Discovery, Jan 21. 2014 Apr;4(4):423-33. doi: 10.1158/2159-8290.CD-13-0440. PMID: 24469106.

H. Escuin-Ordinas, Y. Fu, M. Atefi, A. Cass, C. Ng, R. Huang, B. Comin-Anduix, S. Yashar, A.J. Cochran, R. Marais, R.S. Lo, T.G. Graeber, H.R. Herschman, A. Ribas (2014) COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas induced by BRAF inhibitors, Molecular Oncology, Dec 1. 2014 Mar;8(2):250-60. doi: 10.1016/j.molonc.2013.11.005. PMID: 24345644.

H. Shi, A. Hong, X. Kong, R.C. Koya, C. Song, G. Moriceau, W. Hugo, C.C. Yu, T. Chodon, R.A. Scolyer, R.F. Kefford, A. Ribas, G.V. Long, and R.S. Lo (2013) A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition, Cancer Discovery, Nov. 21.2014 Jan;4(1):69-79. doi: 10.1158/2159-8290.CD-13-0279. PMID: 24265152.

H. Shi, H. Willy, X. Kong, A. Hong, R. C. Koya, G. Moriceau, T. Chodon, R. Guo, D. Johnson, K. Dahlman, R. Kefford, B. Chmielowski, J.A. Glaspy, J. A. Sosman, N. van Baren , G. V. Long, A. Ribas, R. S. Lo (2013) Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy, Cancer Discovery Nov. 21 (cited 44 times). 2014 Jan;4(1):80-93. doi: 10.1158/2159-8290.CD-13-0642. PMID: 24265155.

A. Viros, R. Hayward, S. Yashar, C.C. Yu, M. Martin, A. Zambon, D. Niculescu-Duvaz, C. Springer, R. S. Lo and R. Marais (2012) Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma, Journal of Investigative Dermatology, Aug 16. doi: 10.1038/jid.2012.268. PMID: 22895366.

A. Gembarska, F. Luciani, H. Shi, E. Russel, J. de Lange, D. Yip, J. Goydos, J. J. Haigh, L. Larue, A. Jochemsen, H. Shi, G. Moriceau, R. S. Lo, G. Ghanem, F. Bernal, J-C Marine (2012) MDM4 is a key therapeutic target in melanoma, Nature Medicine, Jul 22. doi: 10.1038/nm.2863. PMID: 22820643.

M. Krauthammer, Y. Kong, P. Evans, M. Choi, A. Bacchiocchi, B. Ha, J. P. McCusker, E. Cheng, S. Ariyan, D. Narayan, K. Dutton-Regester, A. Raefski, M. Bosenberg, M. Sznol, H. M. Kluger, D. E. Brash, D. F. Stern, M. A. Materin, R. S. Lo, S. Mane, S. Ma, K. Kidd, N. K. Hayward, R. P. Lifton, J. Schlessinger, T. J. Boggon, R. Halaban (2011) Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma, Nature Genetics, Jul 29. doi: 10.1038/ng.2359. PMID: 22842228.

R. Strausman, T. Morikawa, K. Shee, M. Barzily-Rokni, Z. R. Qian, J. Du, A. Davis, M. M. Mongare, J. Gould, D. T. Frederick, Z. A. Cooper, P. B. Chapman, D. B. Solit, A. Ribas, R. S. Lo, K. T. Flaherty, S. Ogino, J. A. Wargo, T. R. Golub (2012) Tumor micro-environment elicits innate resistance to RAF inhibitors through HGF secretion, Nature, Jul 26;487(7408):500-4. doi: 10.1038/nature11183. PMID: 22763439.

N. A. Graham, M. Tahmasian, B. Kohli, E. Komisopoulou, M. Zhu, A. Ribas, R. S. Lo, I. K. Mellinghoff, P. S. Mischel and T. G. Graeber (2012) Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death, Molecular Systems Biology, Jun 26;8:589. doi: 10.1038/msb.2012.20. PMID: 22735335.

R. S. Lo (2012) Receptor tyrosine kinases in cancer escape from BRAF inhibitors, Cell Research, advanced online publication May 8, 2012. 2012 Jun;22(6):945-7. doi: 10.1038/cr.2012.78. PMID: 22565288.

H. Shi, G. Moriceau, X. Kong, R. Koya, R. Nazarian, A. Bacchiocchi, K. Dahlman, J. A. Sosman, R. Halaban, R. Kefford, G. V. Long, A. Ribas, and R. S. Lo (2012) Pre-existing MEK1 exon 3 mutations in V600E/KB-RAF melanomas do not confer resistance to B-RAF inhibitors, Cancer Discovery, 2012 May;2(5):414-424. Epub 2012 Apr 1. (In This Issue highlight). doi: 10.1158/2159-8290.CD-12-0022. PMID: 22588879.

K.T. Paraiso, H.E. Haarberg, E. Wood, V.W.Rebecca, Y.A. Chen, Y. Xiang, A. Ribas, R. S. Lo, J.S. Weber, V.K. Sondak, J.K. John, A.S. Sarnaik, J.M. Koomen, K.S. Smalley (2012) The HSP90 inhibitor XL88 overcomes BRAF inhibitor resistance mediated through diverse mechanisms, Clinical Cancer Research, Feb 20. doi: 10.1158/1078-0432.CCR-11-2612. PMID: 22351686.

H. Shi, G. Moriceau, X. Kong, M-K Lee, F. Lee, R. C. Koya, C. Ng, T. Chodon, G. M. Pupo, K. Dahlman, J. A. Sosman, R. F. Kefford, G. V. Long, S. F. Nelson, A. Ribas, R. S. Lo (2012) Melanoma whole exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance, Nature Communications, March 6 10.1038/ncomms1727. PMID: 22395615.

R. S. Lo (2012) Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas, Pharmacogenomics, 13(2), 125-128. doi: 10.2217/pgs.11.166. PMID: 22256862.

F. Su, A. Viros, C. Milagre, K. Trunzer, G. Bollag, O. Spleiss, J. S. Reis-Filho, X. Kong, R. C. Koya, M. J. Kim, R. Hayward, M. Martin, H. Yang, Q. Wang, J. Noe, M. Lambros, F. Geyer, N. Dhomen, I. Niculescu-Duvaz, A. Zambon, D. Niculescu-Duvaz, N. Preece, L. Robert, N. J. Otte, S. Mok, D. Kee, Y. Ma, C. Zhang G. Habets, E. A. Burton, B. Wong, H. Nguyen, J. L. Troy, K. T. Flaherty, P. B. Chapman, R. Gonzalez, T. E. Hutson, I. Puzanov, B. Lestini, K. B. Nolop, R. J. Lee, A. K. Joe, C. J. Springer, J. A. Sosman, G. McArthu, R. S. Lo, A. Ribas, R. Marais (2012) RAS mutations in cutaneous squamous cell carcinomas with BRAF inhibitors, New England Journal of Medicine, Jan 19 366(3):207-15 (Editorial in the same issue). doi: 10.1056/NEJMoa1105358. PMID: 22256804.

P. I. Poulikakos, Y. Persaud, M. Janakiraman, X. Kong, C. Ng, G. Moriceau, H. Shi, M. Atefi, B. Titz, M. Gabay, M. Salton, K. Dahlman, T. Madhavi, J. A. Wargo, K. T. Flaherty, M. C. Kelley, T. Misteli, J. A. Sosman, P. Chapman, T. G. Graeber, A. Ribas, R. S. Lo, N. Rosen, D. B. Solit (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E), Nature, Nov 23 480(7377):387-390 (News & Views in the same issue). doi: 10.1038/nature10662. PMID: 22113612.

R. Nazarian, H. Shi, Q. Wang, X. Kong, R. C. Koya, H. Lee, Z. Chen, M. Lee, N. Attar, H. Sazegar, T. Chodon, S. F. Nelson, G. McArthur, J. A. Sosman, A. Ribas and R. S. Lo (2010) Melanomas acquire resistance to V600EB-RAF inhibition by RTK or N-RAS upregulation, Nature, Dec 16; 468(7329), 973-7. (News & Views in the same issue). doi: 10.1038/nature09626. PMID: 21107323.

H. Shi, X. Kong, A. Ribas, and R. S. Lo (2011) Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition, Cancer Research (Priority Report), 71(15):5067-74. doi: 10.1158/0008-5472.CAN-11-0140. PMID: 21803746.

F. Niehr, E. Euw, N. Attar, D. Guo, D. Matsunaga, H. Sazegar, C. Ng, J. A. Glaspy, R. S. Lo, P. S. Mischel, B. Comin-Anduix, A. Ribas (2011) Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations, Journal of Translational Medicine, 2011 May 24;9:76. doi: 10.1186/1479-5876-9-76. PMID: 21609436.

M. Atefi, E. Euw, N. Attar, C. Chu, D.Guo, R. Nazarian, B. Chmielowski, J. A. Glaspy, P. Mischel, R. S. Lo, and A. Ribas (2011) Reversing cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway, PLOS ONE. 2011;6(12):e28973. doi: 10.1371/journal.pone.0028973. PMID: 22194965.

J. N. Søndergaard, R. Nazarian*, Q. Wang*, S. Mok, H. Sazegar, T. Hsueh, S. Kehoe, L. Macconaill, J. Borretina, N. Attar, J. Zuckerman, B. Chmielowski, B. Comin-Anduix, R. Koya, G. Bollag, P. Mischel, R. S. Lo, A. Ribas (2010) Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific BRAF V600E inhibitor PLX4032/RO5185426, Journal of Translational Medicine, 8, 39.*Equal contributing authors. 2010 Apr 20;8:39. doi: 10.1186/1479-5876-8-39. PMID: 20406486.